Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753272 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 43,695
- Enrollment target
NCT00753272 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 43,695 participants.
The verdict
NCT00753272, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 43,695 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance phase during the influenza peak season.
Interventions
- BIOLOGICAL GSK Bio's influenza vaccine GSK2186877A
- BIOLOGICAL Fluarix TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43,695 participants |
| Start Date | 2008-09-15 |
| Est. Completion | 2011-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753272
The ClinicalTrials.gov registry entry for NCT00753272 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 43,695 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK Bio's influenza vaccine GSK2186877A is the first listed.
NCT00753272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753272 about?
NCT00753272 is a clinical study titled "Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older". The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance ph...
What is the current status of trial NCT00753272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 43,695 participants. The study started on 2008-09-15. Estimated completion is 2011-01-05.
What interventions are being tested in trial NCT00753272?
The interventions under investigation include: GSK Bio's influenza vaccine GSK2186877A (BIOLOGICAL), Fluarix TM (BIOLOGICAL).
Who is sponsoring clinical trial NCT00753272?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.